Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
telbermin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | Topically applied |
| telbermin | DRUG | Topically applied |
Inclusion Criteria: * Ability and willingness to comply with the following: study drug gel application and dressing changes as instructed; use offloading footwear and practice of rubbing prevention (shear injury) of the study ulcer for the duration of the study; adherence to study requirements or u...
Telbermin is an investigational small molecule being developed for the treatment of diabetic foot ulcers. It is administered topically to induce healing of these ulcers. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Telbermin is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy for diabetic foot ulcers.
Telbermin is in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval. A Phase 2 trial has been completed to assess its effect on healing diabetic foot ulcers.
Telbermin has one completed Phase 2 clinical trial, identified as NCT00351767. This study assessed the effect of topical recombinant human vascular endothelial growth factor for induction of healing of diabetic foot ulcers, enrolling 170 participants.
Telbermin is a topical recombinant human vascular endothelial growth factor, as described in the clinical trial title. The study evaluates this agent for inducing healing of diabetic foot ulcers.